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Abstract
microRNAs have emerged as powerful regulators of many biological processes, and their
expression in many cancer tissues has been shown to correlate with clinical parameters
such as cancer type and prognosis. Present in a variety of biological fluids, microRNAs
have been described as a ‘gold mine’ of potential noninvasive biomarkers. Release of
microRNA content of blood cells upon hemolysis dramatically alters the microRNA profile in
blood, potentially affecting levels of a significant number of proposed biomarker microRNAs
and, consequently, accuracy of serum or plasma-based tests. Several methods to detect
low levels of hemolysis have been proposed; however, a direct comparison assessing their
sensitivities is currently lacking. In this study, we evaluated the sensitivities of four methods
to detect hemolysis in serum (listed in the order of sensitivity): measurement of hemoglobin
using a Coulter1 AcT diff™ Analyzer, visual inspection, the absorbance of hemoglobin
measured by spectrophotometry at 414 nm and the ratio of red blood cell-enriched miR-
451a to the reference microRNAmiR-23a-3p. The miR ratio detected hemolysis down to
approximately 0.001%, whereas the Coulter1 AcT diff™ Analyzer was unable to detect
hemolysis lower than 1%. The spectrophotometric method could detect down to 0.004%
hemolysis, and correlated with the miR ratio. Analysis of hemolysis in a cohort of 86 serum
samples from cancer patients and healthy controls showed that 31 of 86 (36%) were pre-
dicted by the miR ratio to be hemolyzed, whereas only 8 of these samples (9%) showed visi-
ble pink discoloration. Using receiver operator characteristic (ROC) analyses, we identified
absorbance cutoffs of 0.072 and 0.3 that could identify samples with low and high levels of
hemolysis, respectively. Overall, this study will assist researchers in the selection of appro-
priate methodologies to test for hemolysis in serum samples prior to quantifying expression
of microRNAs.
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Introduction
A class of small non-coding RNAs known as microRNA plays a central role in almost all
known biological processes. microRNAs are approximately 17–22 nucleotides in length and
when bound to the 3' UTR of target mRNAs, repress gene expression by degradation of target
mRNA or suppressing translation [1–3]. The human genome is estimated to encode more than
1,000 microRNAs, which collectively regulate more than half of all protein coding genes [1–4].
Therefore, it is not surprising that aberrant microRNA expression is linked to development
and progression of many diseases including cancer [1–3, 5, 6]. Furthermore, microRNA signa-
tures of cancer tissues are associated with cancer types and subtypes as well as staging, progres-
sion, prognosis and response to treatments [3, 7–9].
Recently, microRNAs were identified in a range of body fluids including urine, serum,
plasma, tears and saliva, highlighting them as potential ‘gold mines’ of noninvasive disease bio-
markers [5, 6, 10–14]. Serum microRNAs can withstand extreme conditions such as extended
storage, multiple freeze-thaw cycles, high and low pH and even boiling [6, 15, 16]. The encap-
sulation of microRNA into vesicles (exosomes, microvesicles and high-density lipoproteins),
chemical modifications or association with protein complexes such as Ago2, an essential pro-
tein for RNA interference, are all currently thought to provide protection against potent endog-
enous ribonucleases present in the blood [5, 6, 14, 17–20].
The source of microRNAs, collection protocol, extraction and detection methods, as well as
inter-individual variables such as age, diet, race and even altitude have been shown to influence
the ability to robustly determine microRNA levels. These and other pre-analytical and analyti-
cal factors must be addressed in the development of reliable and reproducible microRNA-
based tests for clinical settings [15, 16, 21]. In addition, microRNA content released from
blood cells upon hemolysis can dramatically alter the expression of certain microRNA, and
may lead to false discovery of disease-associated biomarkers [22–24]. One study identified over
half of the proposed microRNA biomarkers of solid cancers have been identified at high levels
in one or more types of blood cells [25]. Further, up to 65% of detectable microRNAs in plasma
have been shown to be affected by hemolysis [23]. While a number of studies have suggested
that miR-16 is suitable as a reference microRNA for normalization of samples [26, 27], it is sig-
nificantly altered by hemolysis, raising some concern for its routine use as a reference micro-
RNA in serum or plasma studies [15, 23].
Currently, there is a lack of consensus on methods to detect low levels of hemolysis in
serum that has the potential to affect the accuracy of microRNA-based tests. Reports have
revealed that serum microRNA content is already altered due to hemolysis before samples
manifest pink discoloration that is visible to the naked eye [23, 24]. In search of methods to
detect low levels of hemolysis, Blondal et al. (2013) suggested that the ratio of red blood cell-
enriched miR-451a to miR-23a, the latter microRNA being unaffected by hemolysis, can be
used as a surrogate indicator of hemolysis [22]. miR-451a:miR-23a ratios of<5, 5–7 and>7
are, respectively, indicative of samples at low, moderate or severe risk of hemolysis [22]. The
spectrophotometric absorbance of hemoglobin has also been suggested as a measure of hemo-
lysis [22, 24]. A direct comparison of these methods has not been previously reported, nor have
their sensitivities to detect low levels of hemolysis in serum been determined.
In this study, we evaluated the sensitivities of four separate methods to detect hemolysis in
serum from healthy volunteers and women with ovarian cancer: (1) Coulter1 AcT diff™ Ana-
lyzer measurement of hemoglobin, (2) visual inspection, (3) spectrophotometric measurement
of absorbance of hemoglobin at 414 nm [22–24], and (4) the ratio of miR-451a to miR-23a
[22].
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Materials and Methods
Blood collection, processing and storage
Written consent was obtained and blood collected from 56 women with high-grade serous
ovarian carcinoma (HGSOC; 64.1 ± 3.4 years) and 30 healthy females age matched within 5
years (61.0 ± 4.7 years) under a protocol approved by the Northern Sydney Local Health Dis-
trict Human Research Ethics Committee (Protocol #0310-209B). For women undergoing sur-
gical resection of their tumor, blood was collected from the peripherally inserted central
catheter (PICC line) prior to the induction of anesthesia. Blood from healthy volunteers was
collected using a 21 gauge needle. In both cases, samples were transferred or collected into a 9
ml BD Vacutainer serum tube (BD #455092, North Ryde, NSW, Australia). Blood was allowed
to clot for 15–30 minutes at 4°C and centrifuged at 3000 rpm for 15 minutes at 4°C. Serum was
carefully withdrawn without disturbing the buffy coat and immediately stored at -80°C in
500 μl aliquots as part of the Kolling Institute Gynecological Tumor Bank. Samples were rap-
idly thawed in a 37°C water bath as required.
Hemolysis dilution series
Whole blood, 0.5 ml collected from a healthy volunteer, was allowed to clot in an eppendorf
tube, and sonicated until the sample was completely fluid and bright red, indicative of a high
degree of hemolysis. Serum was isolated from the blood of a healthy volunteer as per the
healthy volunteers’ protocol described above. This sample, collected under optimal conditions,
was classified as unhemolyzed for the purpose of this study. A hemolysis dilution series com-
prising 100%, 20%, 4%, 1%, 0.25%, 0.062%, 0.016%, 0.004%, 0.001% hemolyzed and unhaemo-
lysed samples (v/v) was prepared by serial dilution of the 100% hemolyzed sample with
unhemolyzed serum.
Assessment of hemolysis
Hemolysis in serum samples was measured using 4 methods. The first method measured
hemogloblin concentration using the Coulter1 AcT diff™ Analyzer and the Tainer Reagent Kit
(Beckman Coulter Inc # 8547135, Lane Cove, NSW, Australia). Three technical replicates were
performed for each sample. The second method to assess hemolysis was simple visual inspec-
tion of serum samples for pink discoloration indicative of free hemoglobin against a white
background. Visual discoloration of each sample was scored from 0 (unhemolyzed serum) to 5
(100% hemolyzed serum). The third method was measurement of the absorbance of hemoglo-
bin at 414 nm using a NanoDrop™ 1000 spectrophotometer (Thermo Scientific, Scoresby, Vic-
toria, Australia), averaging two technical replicates per sample. Lastly, the fourth method used
determined the ratio of miR-451a to miR-23a-3p (delta Cq (miR-23a-3p—miR-451a)) referred
to hereon as the “miR ratio”), with real-time reverse transcription (RT)-PCR using a 7900HT
Fast Real-Time PCR System (Life Technologies, Scoresby, Victoria, Australia). Three RT reac-
tions were performed for each sample followed by one PCR per RT.
RNA extraction and real-time RT-PCR
RNA was extracted from 200 μl serum using the miRCURY RNA isolation kit for Biofluids
(Exiqon #300112, Vedbaek, Denmark) according to the manufacturer’s instructions. One μg
MS2 bacteriophage carrier RNA (Roche #10165948001, Castle Hill, NSW, Australia) was
added during the lysis step. RNA was eluted in 25 μl nuclease-free water twice (final volume
50 μl) and stored at -80°C. RT was performed using 2 μl RNA template per 10 μl RT reaction
using the Universal cDNA Synthesis kit (Exiqon #203301). Three independent RT reactions
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were performed per sample, and one PCR conducted for each. The real-time RT-PCR master
mix contained 100-fold diluted cDNA, 1X ExiLENT SYBR Green master mix (Exiqon
#203420) and 1X ROX reference dye (Life Technologies #12223–012). Ten μl of the master mix
was transferred to each well of a Serum/Plasma Focus microRNA PCR panel (Exiqon #203843)
or Pick-&-Mix microRNA PCR panel (Exiqon #203802) containing locked nucleic acid (LNA)
primers using the epMotion 5070 liquid handling system (Eppendorf, North Ryde, NSW, Aus-
tralia). Real-time RT-PCR was performed on a 7900HT Fast Real-Time PCR System (Life
Technologies). PCR conditions were as follows: 95°C for 10 minutes; followed by 40 amplifica-
tion cycles of 95°C for 10 seconds and 60°C for 1 minute, followed by melting curve analysis.
Statistical analyses
Real-time RT-PCR data was exported and analyzed in GenEx software V6 (Exiqon #207016)
and adjusted for plate-to-plate PCR variability using the spike-in miR UniSP3. Further analyses
were performed in the statistical language R using ‘ggplot2’, ‘ROCR’, ‘verification’, ‘car’ and
‘plotrix’ packages. An average of the technical replicates was calculated for each sample. A P-
value of<0.05 using the student’s t-test assuming equal variance or Mann–Whitney U test was
considered as significant. Results are presented as mean ± 2 × S.E.M. Error bars in all Figs rep-
resent S.E.M.
Results
Sensitivities of four methods to detect hemolysis
Four methods for the detection of hemolysis were compared using the hemolysis dilution series
as described. The Coulter1 AcT diff™ Analyzer measurement of hemoglobin could detect
down to 1% hemolysis, while the 0.25% hemolyzed and the unhemolyzed sample remained
indistinguishable (Fig 1B). By visual inspection alone, the pink discoloration of free-hemoglo-
bin could be detected down to 0.25% hemolysis (Fig 1A and 1C; S1 File). In contrast, the spec-
trophotometric method could detect down to 0.004% hemolysis (Fig 1D). The calculated miR
ratio could detect down to 0.001% hemolysis, the lowest point tested, making it the most sensi-
tive method (Fig 1E). The Coulter1 AcT diff™method was excluded from further analyses due
to its low sensitivity. Therefore, in order of decreasing sensitivity, the methods used can be
ranked as miR ratio> spectrophotometry> visual inspection> Coulter1 AcT diff™ Analyzer.
Next, we determined the hemolysis levels of 86 samples (56 women with ovarian cancer and
30 age-matched, healthy females) using visual inspection, spectrophotometric absorbance and
the miR ratio (S2 File). Using the miR ratio as the ‘gold standard’, 16% (14/86), 48% (41/86) and
36% (31/86) of the samples were found to have low (miR ratio<5), moderate (miR ratio between
5 and 7) or severe (miR ratio>7) hemolysis, respectively, according to the criteria defined by
Blondal et al. (2013), highlighting hemolysis as potentially a problematical factor, even when
serum samples are collected under optimal conditions (Fig 2A). The miR ratio of the unhemo-
lyzed sample used to construct the dilution series was 4.59 ± 0.10. In contrast, the miR ratio for
the 0.25% hemolyzed sample, the limit of visual inspection, was 7.67 ± 0.14. Furthermore, 100%
of the samples with pink discoloration (8/8) had a miR ratio>7, suggesting that any samples
with visible pink discoloration were already severely affected by hemolysis (Fig 2A).
Identification of severely hemolyzed samples using visual inspection
and the absorbance of hemoglobin
Since the majority of the severely hemolyzed samples based on the miR ratio (74%; 23/31) were
visually undetectable, we investigated whether the absorbance of hemoglobin could be utilized
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to detect additional severely hemolyzed samples, i.e miR ratio>7. The samples with pink dis-
coloration had both higher absorbance (0.46 ± 0.11) and miR ratios (8.29 ± 0.51; Fig 2B).
No significant differences were observed between the absorbance of low and moderate
hemolyzed samples as classified by the miR ratio (P = 0.13; Fig 3A); however, low and
Fig 1. Sensitivities of four methods to detect hemolysis. (A) A hemolysis series was prepared by diluting 100% hemolyzed sample with unhemolyzed
serum (0%), and the sensitivity of each method determined by its ability to detect hemolysis (indicated by arrows). (B—E) Detection of hemolysis using four
methods. For visual inspection, samples were scored from 0 (unhemolyzed sample) to 5 (100% hemolysis). Averages of technical replicates are shown
where appropriate. ‘Unhem’ denotes unhemolyzed serum. Absorbance measures (D) and miR ratios (E) are noted on the graphs.
doi:10.1371/journal.pone.0153200.g001
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moderately hemolyzed samples were significantly different from the severely hemolyzed sam-
ples (P<0.001 &<0.0001, respectively). In other words, the miR ratio could further quantify
hemolysis in the samples that were indistinguishable by absorbance. Severely hemolyzed sam-
ples (miR ratio>7) had 1.85-fold higher absorbance than low and moderately hemolyzed sam-
ples combined together (miR ratio<7; P<0.0001; Fig 3B), indicating that the absorbance of
hemoglobin could have predictive value in discriminating severely hemolyzed (miR ratio>7)
samples. The receiver operator characteristic (ROC) curve separated severely hemolyzed sam-
ples from the rest with an area under curve (AUC) of 0.8038 (P<0.0001; Fig 3C). The cut-off
absorbance of 0.3 identified 48.4% (15/31) of hemolyzed samples, of which 8 were visually
undetectable. The accuracy of prediction using this cut-off (True PositiveþTrue Negative
PositiveþNegtive ) was 0.779.
We tested whether a similar analysis could identify an absorbance cut-off below which a
sample is likely to have low levels of hemolysis (miR ratio<5; Fig 3D). Despite similar median
values between the two groups (miR ratio<5 and>5), the cut-off absorbance of 0.072 could
identify samples with a low risk of hemolysis with AUC of 0.7173 (Fig 3E). In general, absor-
bance-based tests to predict hemolysis suffered from low sensitivity, but offered high specificity
and moderate positive and negative predictive values (Table 1).
Impact of hemolysis on hemolysis-sensitive microRNAs
Since the microRNAs affected by hemolysis originate predominantly from the rupture of red
blood cells (RBC), the extent to which a specific microRNA is altered may depend on its abun-
dance in RBC. Using RBC-derived miR-16-5p and miR-15b-3p surrogates for hemolysis-sensi-
tive high and low abundant microRNAs based on Cq values in the cohort as a whole (Fig 4), we
calculated differences in their levels across the 3 categories defined by the miR ratio, especially
for miR-15b-3p as most microRNAs in serum are likely to present at moderate or low levels.
The levels of miR-16-5p and miR-15b-3p increased as the miR ratio increased (Fig 4A and 4B).
miR-16-5p and miR-15b-3p were found to be altered by 5.9-fold (P<0.0001) and 4.5-fold (P
<0.0001), respectively, in the samples at severe risk of hemolysis (miR ratio>7) compared to
Fig 2. Comparison of methodologies for determining hemolysis in serum samples. Serum samples
(N = 86) categorized by low (miR ratio <5; N = 14), moderate (miR ratio 5–7; N = 41) and severe (miR ratio >7;
N = 31) hemolysis. Results of visual inspection are recorded for each category as the proportion of samples
that are clear, cloudy or visibly pink. (B) Absorbance at 414 nm and the miR ratio of the cohort (N = 86). The
dotted line represents the threshold above which samples are considered to be severely hemolysed
according to the miR ratio (>7). Samples are color-coded according to their visual appearance (clear, cloudy
or visibly pink).
doi:10.1371/journal.pone.0153200.g002
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those at low risk (miR ratio<5). Both microRNAs were also found to be elevated by approxi-
mately two-fold between miR ratio categories<5 compared to 5–7, as well as 5–7 compared to
>7. Thus, both high and low abundant microRNAs susceptible to hemolysis are significantly
Fig 3. Identification of samples with low or severe hemolysis by spectrophotometric absorbance. (A) Cohort (N = 86) is grouped by low (miR ratio <5;
N = 14), moderate (miR ratio 5–7; N = 41) and severe (miR ratio >7; N = 31) predicted risk of hemolysis, and absorbance at 414 nm was compared between
groups. No significant differences in absorbance of samples were observed between the low and moderate groups; however, both were significantly different
to the severe hemolysis group. (B-C) Absorbance of samples with miR ratio >7 was 1.85-fold higher than those with miR ratio <7. ROC analysis suggested
that absorbance could predict severely hemolyzed samples (miR ratio >7). The cut-off for absorbance of 0.3 identified by ROC is shown as a dotted red line.
(D-E) ROC analysis revealed a cut-off for absorbance of 0.072 (depicted as a dotted red line) below which samples would be predicted to have low levels of
hemolysis (miR ratio <5). ** P < 0.001, *** P < 0.0001 and ## Mann-Whitney U test P < 0.001. ‘TPR’ and ‘FPR’ refer to true and false positive rates,
respectively.
doi:10.1371/journal.pone.0153200.g003
Table 1. Assessment of performance of the spectrophotometric absorbance of hemoglobin at 414 nm for predicting the miR ratio.
Low risk (miR ratio <5) Severe risk (miR ratio >7)
All samples (N = 86) Clear samples* (N = 77) All samples (N = 86) Clear samples* (N = 77)
Cut-off absorbance 0.072 0.072 0.300 0.300
AUC 0.717 0.733 0.804 0.756
Accuracy 0.849 0.831 0.779 0.779
Sensitivity 0.250 0.250 0.484 0.333
Specificity 0.986 0.984 0.946 0.981
PPV 0.800 0.800 0.833 0.889
NPV 0.852 0.833 0.765 0.765
Absorbance measurements of samples were split into two groups for each comparison: (I) prediction of low risk of hemolysis (miR ratio <5): <5 versus >5,
and (II) prediction of high risk of hemolysis (miR ratio >7): >7 versus <7. ROC analysis was performed for each comparison, and the cut-off absorbance
that maximized the accuracy of prediction was selected. Sensitivity, specificity, PPV and NPV were calculated based on the chosen cut-off.
PPV: positive predictive values
NPV negative predictive values
*refers to samples that did not have a pink discoloration or were cloudy.
doi:10.1371/journal.pone.0153200.t001
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altered amongst 3 categories defined by the miR ratio. miR-23a-3p was present at a similar
level in each of the 3 categories as expected (Fig 4C).
Discussion
Serum microRNAs are attractive non-invasive biomarkers because of their disease-specific
expression and stability in a wide range of conditions. However, a series of pre-analytical and
analytical variables must be considered in the development of robust and reliable microRNA-
based tests [1, 2, 5–7, 9, 15, 16, 21]. The effect of release of the microRNA content of blood cells
upon hemolysis dramatically alters the level of specific serum microRNAs. Recent studies have
shown that 58% (46/79) of proposed microRNA biomarkers [25] for solid cancers were highly
expressed in one or more blood cell types, and up to 65% of detectable microRNAs in plasma
were affected by hemolysis [23]. Hemolysis in clinical samples is common. Reports have sug-
gested that approximately 43% of clinical samples are hemolyzed as determined by free hemo-
globin>0.5 g/L, whereas visual detection indicated by the presence of a pink discoloration is
seen in less than 6% of samples [28, 29]. Therefore, quantifying hemolysis is an essential step
for any procedure measuring circulatory microRNAs for diagnostic purposes or biomarker dis-
covery. A number of methods to measure hemolysis in serum have been described; however, a
direct comparison assessing their sensitivities has not been reported.
In our study of serum, using a 4-fold dilution series, visual inspection could only detect
down to 0.25% hemolysis (v/v). This is comparable to the detection limit of 0.125% (v/v) iden-
tified by Kirschner et al. (2011) using a 2-fold dilution series of plasma [24]. We and others
have shown that visual inspection, i.e. identification of visible pink, as a measure of hemolysis
is insufficient as levels of hemolysis-sensitive microRNA such as miR-451a are already com-
promised prior to visual detection [22, 24].
The ratio of miR-451a to miR-23a-3p was found to be the most sensitive method that could
detect down to 0.001% hemolysis in serum. We quantified hemolysis levels of 86 samples using
Fig 4. Hemolysis-sensitive high and low abundant microRNAs are significantly altered between categories defined by the miR ratio. (A) Levels of
hemolysis-sensitive highly abundant serummicroRNAmiR−16−5p was found to be significantly altered across low, moderate and severely hemolyzed
serum samples defined by miR ratios (B) Levels of a hemolysis-sensitive low abundant microRNAmiR−15b−3p were also different across all miR ratio
categories. (C)miR−23a−3p was present at a similar level amongst three categories, supporting its use as a reference microRNA in determining the miR
ratio. * P <0.05, ** P < 0.001 and *** P < 0.0001.
doi:10.1371/journal.pone.0153200.g004
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the miR ratio, and discovered that hemolysis-sensitive microRNAs miR-15b-3p and miR-16-
5p were significantly affected in the categories of hemolysis (low, moderate and severe) defined
by Blondal et al. (2013) [22]. In particular, the levels of low abundant, hemolysis-sensitive
miR-15b-3p were approximately 4.5-fold higher in the samples with low (miR ratio<5) versus
severe (miR ratio>7) risk of hemolysis. The differences were greater for the more abundant
miR-16-5p between the same groups (5.9-fold).
While the miR ratio was the most sensitive method to detect low levels of hemolysis, it may
not be suitable for all large-scale screening for hemolysis due to additional cost and a relatively
large requirement for starting material (200 μl serum). The absorbance of hemoglobin at 414
nm, on the other hand, is a suitable alternative as it overcomes these restrictions and was found
to be more sensitive than visual inspection in our dataset. We tested whether absorbance could
identify samples that are at a severe risk of hemolysis (miR ratio>7) but remained undetect-
able by visual inspection. ROC analysis revealed that absorbance at 414 nm>0.3 (water as
blank) identified severely hemolyzed samples with accuracy, PPV and NPV of approximately
80% (Fig 5). Over half (8/15) of the samples were visually undetectable. Similarly, Kirschner
et al. (2013) suggested use of absorbance at 414 nm>0.2 (unhemolyzed plasma as blank) to
identify hemolysis in plasma as it reduced variability in miR-451 levels [23]. The different
choices of blanks and serum versus plasma may have led to the differences observed. Interest-
ingly, some samples in our study had lower absorbance than the unhemolyzed serum used in
the dilution series; therefore, water seemed to be an appropriate choice of blank. Similarly,
Fig 5. Assessment of hemolysis in serum samples. All serum samples exhibiting pink discoloration were found to be strongly affected by hemolysis for
microRNA profiling according to the miR ratio. After exclusion of the visibly hemolyzed samples, samples with absorbance at 414 nm of >0.3 are also likely to
be have miR ratio >7, predicting severe hemolysis. In contrast, samples with an absorbance at 414 nm of <0.072 are predicted to have a miR ratio <5.
Samples meeting these criteria may be excluded frommiR ratio for the purpose of determining hemolysis; however, the miR ratio should be determined for
samples with absorbance between 0.072 and 0.3. PPV and NPV refer to positive and negative predictive values after removal of visibly hemolyzed or cloudy
samples, respectively.
doi:10.1371/journal.pone.0153200.g005
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based on our data, samples with absorbance less than 0.072 are likely to be at low risk of hemo-
lysis (miR ratio<5).
Given that a substantial number of circulatory microRNAs are known to be affected by
hemolysis, the miR ratio is recommended as the final quality control step unless clearly indi-
cated in the literature that the microRNA of interest is not affected by hemolysis, for example
miR-122 [15, 30, 31]. If a promising microRNA is found to be sensitive to hemolysis, clinical
interpretation of the test should evaluate the extent to which it is modified by the underlying
condition or disease as well as hemolysis. Since hemolysis is common in clinical samples, this
comparison will also help identify levels of hemolysis that are acceptable in the samples without
significantly affecting the performance of a given test. Failure to meet quality standards would
jeopardize accuracy of measurement in the context of a disease specific relationship of any
microRNA known to be affected by hemolysis. Measuring absorbance of hemoglobin at 414
nm can identify samples that are likely to be at either a low or severe risk of hemolysis, reducing
the total number of samples that would require testing by miR ratio to determine hemolysis.
Despite high specificity, we have shown that the absorbance-based method is inaccurate for
predicting hemolysis between absorbance readings at 414 nm of 0.3 and 0.072, and suggest that
the miR ratio should be used to test for hemolysis in samples that fall within this range. Fur-
ther, bilirubin is known to interfere with the absorbance of hemoglobin, rendering this method
inaccurate in conditions such as jaundice where serum bilirubin levels are elevated [32].
Conclusion
The pivotal role of hemolysis as a quality control measure in any serum microRNA profiling
cannot be underestimated. The ratio of miR-451a to miR-23a-3p proposed by Blondal et al.
(2013) was found to be the most sensitive method to detect low levels of hemolysis, and should
be routinely employed. High and low abundant microRNAs sensitive to hemolysis are signifi-
cantly altered in the three categories of hemolysis (low, moderate and severe) defined by Blon-
dal et al. (2013). Visual inspection to detect hemolysis is insufficient as microRNA in serum
samples that do not display a visible pink discoloration can still show effects of hemolysis, as
shown by a miR ratio>7. Measuring hemoglobin’s absorbance at 414 nm can identify samples
that are likely to be at a low or high risk of hemolysis, therefore reducing the total number of
samples that should be further analysed for hemolysis using the miR ratio test.
Supporting Information
S1 File. Sensitivities of four methods to detect hemolysis. This table shows levels of hemoly-
sis measured by Coulter1 AcT diff™ Analyzer, visual inspection, absorbance at 414 nm and
the miR ratio in the hemolysis dilution series. The values represent averages of technical repli-
cates.
(XLSX)
S2 File. Hemolysis levels in the cohort. This table shows hemolysis levels in 86 serum samples
measured by visual inspection, absorbance at 414 nm and the miR ratio. In addition, levels of
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